Alvogen successfully raised $700 million through the U.S. term loan market in April 2015. The company intends to use the net proceeds from this capital raise to retire existing U.S. and international debt facilities, in addition to promoting its continued expansion in the U.S., South-Asia and Central and Eastern Europe.
Robert Wessman, Chairman and Chief Executive Officer of Alvogen:
“This successful placing will help fund Alvogen’s ambitious plans for future growth. The financing will significantly reduce our overall cost of capital and provide additional resources to support our ongoing journey towards becoming an industry leader,”
Over the last 5 years, Alvogen has built a strong portfolio of more than 200 products which it is expanding into new markets. The company currently has over 60 pending ANDA’s in its pipeline, 28 of which have first-to-file potential. Alvogen also operates five manufacturing and R&D centers in the U.S., South-Korea, Taiwan and Romania. The company currently has commercial operations in 35 countries with 2,300 employees.
Jefferies served as lead arranger on the financing along with Goldman Sachs Lending Partners and SunTrust Robinson Humphrey.